RealTime

Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market

Retrieved on: 
Friday, March 22, 2024
Launch, Ulcerative colitis, Benchmarking, Patient, Gastroenterology, RealTime, Inflammatory bowel disease, FDA, Infliximab, Pharmaceutical industry

The latest results reveal gastroenterologists (n=73) have been slow to incorporate the newest entrants into their already bustling armamentarium, though project rapid adoption over the course of 2024.

Key Points: 
  • The latest results reveal gastroenterologists (n=73) have been slow to incorporate the newest entrants into their already bustling armamentarium, though project rapid adoption over the course of 2024.
  • In terms of unaided awareness of the newly approved medications, Omvoh had the highest recall rates, followed closely by Velsipity and more distantly by Entyvio SC.
  • Conversely, but as expected, Entyvio SC is the most familiar among the three, followed by Velsipity and then Omvoh.
  • The adoption trends regarding gastroenterologist trial rates, overall market share, and average patient initiations exhibit a consistent pattern.

Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights

Retrieved on: 
Thursday, February 8, 2024
Ranibizumab, Ophthalmology, RealTime, Medicare, Regeneron Pharmaceuticals, Physician, AMD, Wet, Genentech, HCP, Macular degeneration, Marketing, Patient, Aflibercept, Pharmaceutical industry

Wet AMD poses a particularly severe threat to vision, necessitating treatment with biologic therapies administered in four to twelve-week intervals.

Key Points: 
  • Wet AMD poses a particularly severe threat to vision, necessitating treatment with biologic therapies administered in four to twelve-week intervals.
  • However, the current treatment landscape often burdens elderly patients with high treatment frequencies, impacting their ability to attend all appointments.
  • Spherix Global Insights conducted an in-depth analysis through its RealTime Dynamix™ report series, delving into the evolving perceptions of ophthalmologists (n=101) regarding approved therapies for wet AMD.
  • In January 2024, ophthalmologists were surveyed on their preferred biologic treatment for wet AMD among other topics.

The effect of new housing supply in structural models: a forecasting performance evaluation

Retrieved on: 
Sunday, February 4, 2024
BET, Section 2, Model, XT, CIT, LTV, Forecasting, Total, Bank, RT, Elasticity, GDP, Website, University of Chicago Press, Process control block, Fiscal, Reproduction, University, WTP, Johns Hopkins University Press, E32, Faculty, Writing, KMR, Monetary economics, Household, Root mean square, YT, GFC, Language, VAR, A6, Motivation, Growth, PLT, Hartman–Grobman theorem, Research, House, Observation, Friction, Section 4, Classification, Macroeconomic model, BAA, AP, Kálmán, Odyssean Wicca, Parameter, Blue chip, A5, HPT, Mark Gertler, Learning, Smets, Inflation, ECB, Q2, Trade, CE, Hit, SPF, Review of Economic Dynamics, ZBW, Kolasa, LTM, R21, Patient, Prior, Shock, Movement, ZT, Australasian, M1, Lens, Great, Nobuhiro, European Central Bank, Estimator, Policy, LTI, COVID-19, Attention, HP, Feedback, Goethe University Frankfurt, International Journal of Forecasting, Federal Reserve, Federal Reserve Bank, Behavior, Health, Blue Chip Economic Indicators, Inverse, Zero lower bound, The Blue, Journal of Applied Econometrics, Economic forecasting, Matrix, Economy, Federal, R31, LTP, Chinese Blackjack, WTI, CES, Sim, Bit, Section 5, Capital market, Quantitative Economics, Credit, Motion, Central bank, Journal of Political Economy, Political economy, Taylor & Francis, Journal of Monetary Economics, Act, Binning, CPT, DPT, Point, MCMC, RealTime, Literature, Metropolis–Hastings algorithm, ZLB, TFP, Research Papers in Economics, Del Negro, GBT, Communication, Kalman filter, Markov, Cycle, Business cycle, Eurozone, DFF, PDF, Filter, Medical classification, American Economic Journal, Demand shock, Comparison, Employment, KTEH, Cobb–Douglas production function, Nonprofit organization, Sampler, PTW, Par, Liquidity trap, Paper, Nominal interest rate, QT, Exercise, Monetary policy, RTD, Interest rate, A7, University of Cambridge, Control, Statistics, Posterior, Pressure, American Economic Review, E37, Financial intermediary, Social science, Basel II, Delphic, Depreciation, European Economic Review, HPD, Ai, Calendar, E17, Government, Journal of Econometrics, HTM, Freedom, LTE, Probability, Face, Calibration, Oxford University Press, New Keynesian economics, Sun, HH, Me, Uncertainty, FPI, Production, Dynamics, Handbook, Real estate
Key Points: 

    Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors

    Retrieved on: 
    Monday, January 22, 2024
    Need for Speed, Psoriatic arthritis, Patient, US FDA, RealTime, TNF, Joint, Rheumatology, Mechanism of action, HCP, Skin, Secukinumab, MOA, Physician, Pharmaceutical industry

    However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.

    Key Points: 
    • However, recent years have witnessed a transformative shift in both the US and EU markets, as rheumatologists increasingly favor alternative mechanisms, notably IL-17 inhibitors.
    • In contrast, within that timeframe, rheumatologists saw a preference for IL-17s more than double, indicating a noteworthy transformation in treatment preferences.
    • Over half of rheumatologists cite efficacy as their primary motive for favoring IL-17 inhibitors in PsA treatment, regularly underscoring the class’s success in treating both skin and joint manifestations.
    • As the treatment landscape for PsA undergoes dynamic changes, staying ahead of these shifting trends becomes essential for effective patient management and optimal treatment outcomes.

    RealTime Software Solutions Reports Record Growth in 2023, Emerging as the Premier Clinical Trial Management Solution for Clinical Research Sites

    Retrieved on: 
    Wednesday, January 17, 2024
    SAN, Devana, Clinical trial, CTMS, Clinical data management, PROPEL, RealTime, Growth, Pharmaceutical industry

    Stephen Johnson, CEO of RealTime Software Solutions, reflects on the landmark year, stating, "The previous year has been transformative for RealTime.

    Key Points: 
    • Stephen Johnson, CEO of RealTime Software Solutions, reflects on the landmark year, stating, "The previous year has been transformative for RealTime.
    • This evolution is a testament to our team's commitment to improving clinical trial management with state-of-the-art eClinical solutions."
    • Exponential User Adoption: Adopted by over 3,000 clinical research sites worldwide, RealTime has experienced a rapid surge in user growth.
    • Collaborations with clinical research sites worldwide have contributed to the platform's widespread adoption and recognition as a global leader in clinical trial management solutions.

    U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement

    Retrieved on: 
    Wednesday, December 13, 2023
    AB, Traffic barrier, HCP, FDA, Multiple sclerosis, RealTime, Neurology, BTK, Merck Serono, Patient, Safety, Non-Euclidean geometry, RMS, Pharmaceutical industry

    Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS).

    Key Points: 
    • Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS).
    • As orally administered BTKis are already established in oncology, there was a notable level of awareness, familiarity, and anticipation surrounding these developmental assets amongst neurologists.
    • Through Spherix’s quarterly RealTime Dynamix™ market tracker, neurologists and MS specialists have expressed an increasing level of enthusiasm for these investigational therapies over time.
    • With the recent trial outcomes impacting two of the prominent BTKis in development, the optimistic prospects for this class now face uncertainty.

    FibroGen/Astellas’ EVRENZO (roxadustat) Making In-Roads in European Market as In-Class Challenger, Akebia/Medice’s VAFSEO (vadadustat), Prepares for Launch in Early 2024.

    Retrieved on: 
    Friday, December 8, 2023
    Akebia, Anemia, European Commission, Nephrology, Peritoneal dialysis, RealTime, GSK, Traction, Patient, Dialysis, History, CKD, Pharmaceutical industry

    Meanwhile, GSK, the marketer of the sole approved HIF-PHI in the US, withdrew its application in July 2023, opting against introducing JESDUVROQ into the European market.

    Key Points: 
    • Meanwhile, GSK, the marketer of the sole approved HIF-PHI in the US, withdrew its application in July 2023, opting against introducing JESDUVROQ into the European market.
    • Particularly in the German market, nearly all nephrologists report that they have already begun gaining clinical experience with EVRENZO, with notably high levels of satisfaction.
    • The utilization of EVRENZO among non-dialysis patients has grown across various stages, encompassing Stage 3, Stage 4, and Stage 5 patients.
    • Anticipation runs high for Akebia/Medice’s forthcoming VAFSEO in the dialysis sector, which is set for an official near-term launch in 2024.

    BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake

    Retrieved on: 
    Thursday, December 7, 2023
    Family, Risk, Johnson & Johnson, Aes, Infection, Q4, Physician, HCP, FDA, Thrombosis, RealTime, Venereology, JAK, BMS, Launch, Benchmarking, Patient, Safety, Psoriasis, TYK2, Malignancy, LTE, TYK, Pharmaceutical industry

    There's apprehension surrounding potential side effects and adverse events, notably cardiac incidents, malignancy, thrombosis, and the risk of infection.

    Key Points: 
    • There's apprehension surrounding potential side effects and adverse events, notably cardiac incidents, malignancy, thrombosis, and the risk of infection.
    • One participating dermatologist highlights, “even though it's not a direct JAK inhibitor, it still is in that same family.
    • Contact rates between BMS sales representatives and healthcare professionals have consistently increased, with the majority now reporting interactions with a Sotyktu representative since launch.
    • An influential factor in reshaping safety perceptions regarding the oral psoriasis treatment involves BMS’ ongoing long-term-extension (LTE) trial, known as POETYK.

    When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…

    Retrieved on: 
    Thursday, November 30, 2023
    Marketing, IBD, Failure, Adalimumab, Risankizumab, MOA, Gastroenterology, Physician, Ustekinumab, HCP, Ulcerative colitis, Injection, UC, RealTime, JAK, Patient, Celltrion, Upadacitinib, Pharmaceutical industry

    Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.

    Key Points: 
    • Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.
    • The first line of UC treatment remains overwhelmingly dominated by the firmly established anti-TNF therapies (such as Humira and Remicade) alongside Entyvio.
    • Furthermore, the favored choice among physicians in Crohn’s disease (CD), Stelara, has continued to enjoy a position in later-line UC treatment.
    • Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

    US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra

    Retrieved on: 
    Monday, November 13, 2023
    HCP, Ustekinumab, Pfizer, Q3, JAK, Takeda, Patient, MOA, AbbVie, Colitis, Ulcerative colitis, Benchmarking, IBD, Launch, Upadacitinib, BMS, S1P, Infliximab, Adalimumab, Gastroenterology, Celltrion, UC, RealTime, Pharmaceutical industry, Tofacitinib, Vedolizumab, Lilly

    These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.

    Key Points: 
    • These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.
    • However, the influx of innovative agents suggests that upcoming changes are poised to be more substantial and transformative.
    • This extension enjoys the highest pre-launch familiarity and generates significantly higher interest in gaining approval.
    • Although prescribers display significant enthusiasm for Entyvio SC, its anticipated impact on the broader market is projected to be modest.